Last reviewed 2026-04-23 · How we verify

RPC1063

RPC1063 is a sphingosine 1-phosphate receptor modulator.

RPC1063 is a sphingosine 1-phosphate receptor modulator. Used for Relapsing forms of multiple sclerosis.

At a glance

Mechanism of action

It works by selectively modulating sphingosine 1-phosphate receptor 1 (S1P1), which is involved in the regulation of lymphocyte trafficking and immune responses.

Approved indications

• Relapsing forms of multiple sclerosis

Common side effects

• Headache
• Nasopharyngitis
• Nausea
• Diarrhea
• Fatigue

Key clinical trials

• Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis (PHASE2, PHASE3)
• Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
• Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
• An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice (PHASE4)
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis (PHASE3)
• An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (PHASE3)
• A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• RPC1063 CI brief — competitive landscape report
• RPC1063 updates RSS · CI watch RSS
• Celgene portfolio CI